NZ223894A - Active substance-containing plaster for controlled administration of active agents to skin - Google Patents

Active substance-containing plaster for controlled administration of active agents to skin

Info

Publication number
NZ223894A
NZ223894A NZ223894A NZ22389488A NZ223894A NZ 223894 A NZ223894 A NZ 223894A NZ 223894 A NZ223894 A NZ 223894A NZ 22389488 A NZ22389488 A NZ 22389488A NZ 223894 A NZ223894 A NZ 223894A
Authority
NZ
New Zealand
Prior art keywords
active substance
skin
substance reservoir
plaster
reservoir
Prior art date
Application number
NZ223894A
Inventor
Hans Rainer Hoffmann
Karin Wolter
Gunter Simon
Peter Barth
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NZ223894A publication Critical patent/NZ223894A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H37/00Accessories for massage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

A plaster containing active ingredients for controlled administration of active ingredients to the skin and possessing a rear side and a skin side, has a rear layer, an active ingredient reservoir containing one or more active ingredients arranged essentially perpendicular to the surface of the plaster in contact with the skin, and an adhesive device on the skin side and possibly a covering layer which is detached before application of the plaster. At least one active ingredient reservoir part (12) can be detached on to the skin while one or more active ingredient reservoir parts remain. For this purpose, the part (13) of the active ingredient reservoir remaining on the skin adheres more strongly to the skin than to the rear side (11).

Description

<div id="description" class="application article clearfix"> <p lang="en" class="printTableText">22 3 8 94 <br><br> * <br><br> Priority Date(s): .. .^B&gt;. .4-^.^&gt;7?." <br><br> Complete Specification Filed: <br><br> Class: fh i&amp;. fry <br><br> . A ,W\ <br><br> Publication Date: ?ZM.W <br><br> P.O. Journal, No: .... I <br><br> Patents Form No. 5 <br><br> ., - i f j x:--5v o <br><br> NEW ZEALAND <br><br> PATENTS ACT 1953 COMPLETE SPECIFICATION <br><br> \ ?5HAR!9S8 <br><br> . C <br><br> "C ? fr J \J <br><br> 7$$ <br><br> x <br><br> ACTIVE SUBSTANCE-CONTAINING PLASTER FOR THE CONTROLLED ADMINISTRATION OF ACTIVE SUBSTANCES TO THE SKIN, THE USE THEREOF AND A PROCESS FOR THE CONTROLLED ADMINISTRATION OR-ACTIVE SUBSTANCES TO THE SKIN <br><br> Y/We, LTS- LOHMANN THERAPIE-SYSTEME GMBH &amp; CO.KG, <br><br> Irlicher Str. 55, 5450 Neuwied 12, Federal Republic of Germany, a Germany company hereby declare the invention, for which /?7we pray that a patent may be granted to {S^/us, and the method by which it is to be performed, to be particularly described in and by the following statement: <br><br> - 1 - <br><br> (followed by page la) <br><br> la <br><br> 22 3 8 9 4 <br><br> DESCRIPTION <br><br> The invention relates to an active substance-containing plaster for the controlled administration of active substances to the skin, which has a back and a skin side, with a back layer, an active substance reservoir subdivided substantially perpendicularly to the skin contact surface of the plaster and having one or more active substances, a contact adhesive device on the skin side and optionally a cover layer detachable prior to the application of the plaster, it being possible to reduce the size of the active substance release surface of the plaster by a predetermined amount by removing part of the active substance reservoir, as well as the use thereof and a process for the controlled administration of active substances to the skin. <br><br> The invention more particularly relates to those plaster used as transdermal therapeutic systems for the controlled administration of medical active substances or also cosmetically active substances to the human or animal skin. A therapeutic system is a medicament or active substance-containing means or administration form, which delivers one or more active substances in continuous manner, at a predetermined rate and over a given time interval to a predetermined application point. These systems are therapeutic precision instruments, whose construction requires extraordinary measures in order to ensure continuous active substance release. <br><br> Plaster-like therapeutic systems have already been developed for the most varied uses and, apart from a t opical effect, a systemic effect can also be obtained. The multiplicity of active substances applicable in this way and their different chemical, physical and pharmacological characteristics make it impossible to cover all therapeutic problems with a single system. <br><br> Numerous therapeutic systems for the administration of medical active substances to the skin are known, a summary being e.g. provided in Klaus Heilmann "Therapeutische Systeme", Ferdinand Enke Verlag, <br><br> (followed by page 2) <br><br> 0 <br><br> •r'» '€ <br><br> &lt; <br><br> i o <br><br> Vm* <br><br> O <br><br> O <br><br> 11 3 8 9 4 <br><br> - 2 - <br><br> Stuttgart, 1977. The prior art systems were not able to provide a completely satisfactory action in all cases. <br><br> I In the conventional structure of a transdermal plaster-like therapeutic <br><br> | system there is an active substance reservoir, vhich contains the <br><br> $ <br><br> I active substance in solid, liquid or dissolved form and a pressure- <br><br> f sensitive adhesion layer (contact adhesive), through which the system <br><br> | is closely linked with the skin. It is important that a whole-area <br><br> | contact is ensured between the active substance release surfaces to <br><br> 1 the skin throughout the application of the system, in order to make <br><br> | sure of the active substance release kinetics. This can be achieved <br><br> { not only through an uninterrupted adhesion layer, but also by rest- <br><br> ] <br><br> | ricted adhesion areas in the skin contact layer of the plaster. <br><br> i <br><br> Although the hitherto known plaster-like therapeutic system permit a uniform or continuously decreasing application of an active substance over a predetermined time, they do not permit specific active substance release kinetics, such as a planned reduction of the active substance release after a predetermined time, or a graduated active substance release quantity'per unit of time. <br><br> This measure is e.g. necessary if the active substance dose has to be reduced in a planned manner during the application period for therapeutic reasons. The same problem arises if, during the application of a combination product, one active substance in the combination must be interrupted after a predetermined time. In such cases, it is in principle possible to solve the problem by using two transdermal plasters, whereof one is removed at the given time. However, this leads to problems for patients, particularly if they are aged. Therefore it is easy to forget to apply the second plaster. In a combination of two plasters with different active substance release surfaces, there is also a risk of choosing the incorrect combination (two identical plasters), or the removal of the wrong plaster. The same complications occur if plasters with different active substances have to be combined and there is in this case also the problem of double <br><br> 22 3 8 9 4 <br><br> - 3 - <br><br> storage. Thus, the use of two plasters leads to numerous disadvantages and the avoidance thereof forms an objective of the invention. <br><br> The proposal of combining two plasters, whereby part thereof can be detached with the aid of a predetermined breaking line, admittedly Improves compliance, but leads to handling problems. Thus, the part to be detached can only be handled by raising from the skin and in undesired manner at least a part of the plaster still remaining on the skin is raised and must be firmly held during detachment. Thus, pressure is exerted on the sensitive transdermal system, which can negatively influence the active substance release rate. <br><br> US Patent 4 297 995 describes a manipulatable active substance plaster, in which the active substance reservoir is subdivided, but is integrated into a single plaster. The active substance reservoir parts are arranged in concentric rings about a disk-like central portion. The overall construction of the plaster with a mechanical fixing of the reservoir to the back layer only makes it possible to change the active substance release surface prior to the application of the plaster, i.e. prior to plaster application the doctor/patient can choose which dose is to be administered, but for changing the active substance release during plaster application, the plaster must be raised from the skin, whilst interrupting therapy and this can also lead to damage and contamination to the plaster support surface. <br><br> As yet no satisfactory solution has been found for the associated problems of repositioning and the permanent refixing of the system to the skin. <br><br> Therefore the problem of the present invention is to provide an improved therapeutic transdermal system, which makes it possible to realize more complicated changes to the active substance release than have hitherto been possible. <br><br> This problem is solved by a plaster of.the aforementioned type, which characterized in that at least part of the active substance reservoir <br><br> 22 3 <br><br> - 4 - <br><br> can be detached, whilst leaving one or more parts of said reservoir on the skin and the part of the active substance reservoir left behind on the skin has a better adhesion to the skin than to the back layer. <br><br> Due to the fact that, according to the invention, the active substance reservoir is partly detachable whereby the part of the active substance reservoir which is not to be detached has a greater adhesion to the skin than to the back layer, after removing a predetermined plaster part with the active substance reservoir part adhering thereto, there is left behind a predetermined active substance reservoir part on the skin, which can e.g. be alone removed following the desired application period. Advantageously the active substance reservoir of the inventive plaster is in two parts. <br><br> In the case of given therapies with varying or marked concentration-fluctuating active substance administrations, it can also be advantageous for the active substance reservoir to be in three parts. The active substance release surfaces of the active substance reservoir parts can be geometrically identical or different. The active substance release surfaces can be juxtaposed, or one active substance reservoir part can completely surround one or more other active substance reservoir parts, considered in a flat or surface-based manner. The subdivision of the partial surfaces is dependent on the therapeutic requirements. Thus, e.g. one active substance reservoir part can circularly surround one or more other active substance reservoir parts. <br><br> The release surface - size ratio of one active substance reservoir part to another is preferably in the range between approximately 1:1 and 1:10. The same active substance or the same active substance combination can be present in all the active substance reservoir parts. <br><br> Particularly preferred products are plasters with the following active substances, but it is also possible to process random other trans-dermally administrable active substance combinations known to the medical Expert: asthma/bronchodilators, such as e.g. clenbuterol, proctaterol and salbutamol and vasodilators, such as e.g. bencyclane and cinnarizine. <br><br> 3 . <br><br> u„, .a. )&amp;kwl*a.at <br><br> 22 3 O b 4 <br><br> $'• " ** "f ^ A <br><br> •» <br><br> - 5 - <br><br> Thus, with the aid of the inventive plaster, in such cases it is possible to reduce the administration dose in planned and controlled <br><br> &lt;88k <br><br> Crx? manner during application. <br><br> However, the active substance reservoir parts can also contain different active substances or different active substance combinations, so that during application it is possible to interrupt or stop one C active substance or active substance combination. Examples for diff erent active substances in the active substance reservoir parts are: oestrogen/gestagen (contraceptives), dexamethasone/prednisolone (in the case of inflammatory, rheumatic muscle and joint diseases), nitroglycerin/ p-blockers (for cardiac diseases), phenytoin/phenobarbital/ caffeine (for epilepsy) and amitriptyline/chlordiazepoxide (psycho-pharmaceuticals) . <br><br> All suitable active substances belong to the groups having either a topical or systemic action. In at least one active substance reservoir part there can be different active substance/active substance combinations as compared with the other active substance reservoir part or parts. <br><br> w' The preferred use of the inventive plasters is in local and systemic, <br><br> transdermal active substance administration in human or animal medicine or in cosmetics. <br><br> The invention is described in greater detail hereinafter relative ^—' to non-limitative embodiments and with reference to the attached drawings, which are not true to scale and wherein show: <br><br> Fig. 1 a cross-section through a first embodiment of an inventive plaster with a two-part active substance reservoir. <br><br> Fig. 2 a plan view of the skin side of a second embodiment of the inventive plaster without a protective layer. <br><br> Fig. 3 a cross-section along line I-I of fig. 2. <br><br> -w-.w, <br><br> " " " —♦.-t.-v <br><br> 22 3 8 9 4 <br><br> - 6 - <br><br> Fig. 4 a plan view of the skin side of a third inventive embodiment without protective layer <br><br> Fig. 5 a cross-section through the embodiment of fig. 4 along line <br><br> II-II on a larger scale. <br><br> Fig. 6 a plan view of the skin side of a fourth embodiment of the invention without a protective layer. <br><br> Fig. 7 a cross-section through the embodiment of fig. 6 along line <br><br> III-III. <br><br> Fig. 8 a cross-section through a fifth embodiment of the invention. <br><br> Fig. 9 a cross-section through a sixth embodiment of the invention. <br><br> Fig. 10 a plan view of the skin side of another embodiment of an inventive plaster with a three-part active substance reservoir and without a protective layer. <br><br> Fig. 11 a larger scale cross-section along line IV-IV of fig. 10. <br><br> The preferred embodiments of the invention shown in the individual drawings will now be described. The active substance reservoir part left last on the skin is referred to as the first active substance reservoir part, whilst the second and third active substance reservoir parts are those which are detached with the back layer. <br><br> t f <br><br> Fig. 1 shows a preferred embodiment of an inventive, optionally circular or angular plaster with a two-part, contact adhesive active substance reservoir in cross-section. The second active substance reservoir part 12 directly adheres to the back layer 11 and is separated from the first contact adhesive active substance reservoir part 13 by a reservoir separating layer 14, which can be constructed as a gap or space between the active substance reservoir parts, or can be filled by an inert separating material. Active substance reservoir part 13 adheres to the back layer 11 by means of a peel-off layer 15, which brings about a gradual adhesion of the two active substance reservoir parts 12,13 to the back layer. The peel-off layer 15 can e.g. be a polymer or metal film or foil, a textile fabric or a laminate <br><br> 22 3 <br><br> - 7 - <br><br> thereof and following the removal of the back layer 11 with the second active substance reservoir part 12 forms a protective layer for the first active substance reservoir part 13 left on the skin in order to protect the latter. The adhesion of the first active substance reservoir part 13 to the skin must be greater than the adhesion between the peel-off layer 15 and the back layer 11. The protective layer 16 is removed prior to the application of the plaster. By. the use of the same dotting system for the surfaces representing the active substance reservoir parts 12,13 in fig. 1, it is made clear that in both active substance reservoir parts 12,13 there is the same active substance or active substance combination, so that with the plaster according to fig. 1 it is possible to bring about a gradual decrease of the active substance release to the skin. <br><br> Fig. 2 is a plan view of the skin side of a further inventive angular plaster with a two-part, non-contact adhesive active substance reservoir, from which the protective layer has already been removed. Thus, on the skin side, the plaster has contact adhesive layers 21,22, which are separated from one another by the inert reservoir separating layer 23, which can once again be a simple gap or an inert material. <br><br> Fig. 3 is a cross-section through the embodiment shown in fig. 2 along line I-I thereof. , The non-adhesive active substance reservoir parts 24,25 are fixed at the back by a contact adhesive layer 27 to the back layer 28, the first active substance reservoir part 24 adhering to the back layer by means of a peel-off layer 26 located between the first contact adhesive layer 27 and the first active substance reservoir part 24. Peel-off layer 26 is designed in such a way that its adhesion to the first active substance reservoir part 24 is greater than to the contact adhesive layer 27. Thus, on detaching the back layer 28 and the second active substance reservoir part 25 fixed by means of the contact adhesive layer 27 to the back layer 28, peel-off layer 26 together with the first active substance reservoir part 24 remains on the skin and assumes for said remaining part 24 the function of a protective layer protecting the reservoir material from <br><br> 22 3 8 9 4 <br><br> - 8 - <br><br> contamination and damage from the outside or also against the escape of e.g. volatile active substance components. <br><br> The skin side contact adhesive layers 21,22 on the non-adhesive active substance reservoir parts 24,25 are so adjusted that the adhesion of the contact adhesive layer 22 of the first active substance reservoir part 24 to the skin is greater than the adhesion between peel-off layer 26 and contact adhesive layer 27. The differently represented surfaces in the drawing are intended to show that there are different active substances or active substance combinations in both active substance reservoir parts 24,25. <br><br> Fig. 4 shows another preferred embodiment of an inventive plaster in plan view on the skin side thereof. The oval plaster has a two-part active substance reservoir and a contact adhesive layer 41 responsible for the fixing of the active substance reservoir parts 42,43 to the back layer 45 also forms the fastening to the skin of the therapeutic system. <br><br> Fig. 5 shows a larger scale cross-section along line II-II of fig. 4. The contact adhesive active substance reservoir parts 42,43, which are separated from one another by an inert reservoir separating layer 46, in this case in the form of a gap, are surrounded in bag-like manner by the back layer 45 carrying a contact adhesive layer 41. <br><br> Here again a separating layer 44 ensures that the adhesion of the first active substance reservoir part 42 to the skin is greater than the adhesion between the peel-off layer 44 and the contact adhesive layer 41 and also ensures that the first active substance reservoir part 42 left on the skin after detaching the second active substance reservoir part 43 and the back layer 45 is protected by a layer. <br><br> The two active substance reservoir parts 42,43 contain different active substances or active substance combinations, as is made clear by the arrangement of the surfaces. <br><br> Fig. 6 shows another inventive plaster with a two-part active substance <br><br> 22 3 <br><br> - 9 - <br><br> reservoir, in which one active substance reservoir part 61 concentrically surrounds the other active substance reservoir part 63, the representation being from the skin side and with the protective layer removed. The contact adhesive, first circular active substance reservoir 63 is separated from the circular second active substance reservoir 61 by an inert reservoir separating layer 62, which can also be in the form of a gap. This embodiment has the advantage that on reducing the active substance release surface by removing part of the plaster with the second active substance reservoir part 61 and together with the back layer 65, it is possible to freely choose the plaster removal direction. <br><br> Fig. 7 shows a cross-section through the embodiment of fig. 6 represented along line III-III thereof. The circular, second active substance reservoir part 61 is directly adjacent to the back layer 65, whilst the peel-off layer 64 is arranged between the circular, first active substance reservoir part 63 and the back layer 65. The adhesion of the first active substance reservoir part 63 to the skin and that between the peel-off layer 64 and the back layer 65 is greater than the adhesion between the peel-off layer 64 and active substance reservoir part 63, so that on removing the back layer 65 the second active substance reservoir part 61 is removed, whilst leaving the first active substance reservoir part 63 on the skin and which is now covered by the peel-off layer 64. The inert reservoir separating layer 62 separates active substance reservoir parts 61,63. In this embodiment, the active substance is the same in both active substance reservoir parts 61,63. <br><br> Fig. 8 shows another preferred embodiment of the invention in cross-section, in which the two parts of a non-adhesive active substance reservoir are once again constructed as a circular disk 82 with a surrounding ring 81. They are separated from one another by an inert reservoir separating layer 83. Back layer 88 is covered by a contact adhesive layer 87, which is directly in contact with the second active substance reservoir part 81. <br><br> - 10 - <br><br> Between the contact adhesive layer 87 and the first active substance reservoir part 82 is provided an inert peel-off layer 86, which is so designed that its adhesion to the contact adhesive layer 87 is less than the adhesion between the contact adhesive layer 85 and the skin. The remaining adhesion values on the boundary layers of said plaster part must naturally be above the adhesion value to the skin. The skin side contact adhesive layers 84,85 of the active .substance reservoir parts 81,82 ensure contact with the skin and prior to the application of the inventive plaster are advantageously covered by a protective layer 89. <br><br> In this embodiment, both active substance reservoir parts 81,82 have different active substances or active substance combinations. <br><br> Fig. 9 shows a cross-section through another embodiment of the invention, in which the back layer 95 surrounds the concentric arrangement of the contact adhesive active substance reservoir parts 91,92 to the skin side. For fixing the overall plaster and the active substance reservoir parts to the skin, the whole surface of back layer 95 is covered with a contact adhesive layer 93. To the latter adheres the second active substance reservoir part 91 in a direct manner, whilst the first active substance reservoir part 92 is fixed via a peel-off layer 94. The adhesion of peel-off layer 94 to the active substance reservoir part 92 is above and the adhesion of layer 94 to contact adhesive layer 93 is below the adhesion between the first active substance reservoir part 92 and the skin. This permits a selective removal of back layer 95 together with the second active substance reservoir part 91. Through a corresponding change to the structure, it is also possible to bring about a selective removal of the first active substance reservoir part 92. Reference numeral 96 designates the inert reservoir separating layer or the gap between the active . substance reservoir parts 91,92. Up to application, the overall arrangement is covered by a detachable protective layer 97. The active substances or active substance combinations are different in both reservoir parts 91,92 in this embodiment. <br><br> 22 3 8 9 <br><br> - 11 - <br><br> Another preferred embodiment of the invention with a three-part active substance reservoir is shown in fig. 10. The latter is a plan view of the skin side of an inventive plaster without the protective layer. A first, circular, contact adhesive active substance reservoir part <br><br> 105 is surrounded by a second, circular, contact adhesive active substance reservoir part 103 and is separated therefrom by an inert reservoir separating layer 104. The third contact adhesive active substance reservoir part 101 surrounds the second active substance reservoir part 103 in concentric ring form. Between the second and third active substance reservoir parts 101,103 is provided a further inert reservoir separating layer 102. Fig. 11 is a larger scale cross-section along line IV-IV. <br><br> Active substance reservoir part 101 adheres directly to back layer 108. A first peel-off layer 106 connected to back layer 108 covers the active substance reservoir parts 103,105. The adhesion thereof to the back layer 108 is less than the adhesion of the active substance reservoir parts 103,105 to the skin, so that active substance reservoir parts 103,105 remain on the skin on removing the back layer 108 with active substance reservoir part 101. Thus, the first peel-off layer <br><br> 106 then forms a protective, new layer for the remaining parts of the plaster. The contact adhesive active substance reservoir part <br><br> 103 adheres directly to the first peel-off layer 106 and can be removed together with the latter in a further removal step, whilst leaving behind on the skin the first active substance reservoir part 105, <br><br> this being made possible by the second peel-off layer 107 between the first active substance reservoir part 105 and the first peel-off layer 106. The adhesion of the second peel-off layer 107 to the first layer 106 is less than the adhesion of the first active substance reservoir part 105 to the skin. The inert reservoir separating layers 102,104, which can also be formed by gaps, are located between active substance reservoir parts 101,103 or 102,105. The chosen example shows for active substance reservoir parts 103,105 the same active substance or active substance combination, indicated by the identical dotting in fig. 11, whilst the active substance reservoir part 101 <br><br> - 12 - <br><br> 22 3 8 <br><br> has a different active substance or active substance combination. <br><br> The drawings which merely illustrate the invention in an exemplified manner, are not intended to restrict the invention either as regards geometrical shape, the association of specific individual components, or as regards the size of the active substance release surfaces. <br><br> As is well known to the Expert in this field, all these quantities can be adapted to the therapeutic requirements and obviously account must be taken of rational production. The part of the active substance reservoir part to be detached can also have a peel-off layer, which then has a greater adhesion to the back layer than the peel-off layer of the reservoir part remaining on the skin. This construction is advantageous if the active substance reservoir parts are to have the same thickness. The contact adhesive layers, particularly those on the skin side, can have contact adhesive-free areas for improved active substance permeability, or can be constructed solely as individual contact adhesive surfaces, e.g. can be embedded in the active substance reservoir material. The release of the active substances from the active substance reservoir parts can optionally be regulated by control membranes, which are embedded in per se known manner in the reservoir mass in one or more active substance reservoir parts, or can be located between the active substance reservoir and the skin side contact adhesive layer, or{ within the skin side contact adhesive layer. <br><br> For the construction of an active substance reservoir, as used according to the invention, it is possible to use the standard measures and materials. The basic materials can be constituted by low and high molecular weight, natural and/or synthetic substances, whose choice is a function of the characteristics of the active substances to be administered and the therapeutic requirements. Apart from the basic material, the active substance reservoir can also contain further suitable additives known or obvious to the Expert on the basis of his knowledge, such as e.g. solubilizers, softeners, plasticizers, tackifiers, stabilizers, fillers and enhancers. The composition in the reservoir parts can be the same or different, which is once again dependent on the active substances to be administered and the desired <br><br> 22 3 8 9 4 <br><br> - 13 - <br><br> release rates or kinetics. In the case of an identical reservoir composition and only one active substance to be administered, it can be appropriate to have a graduated concentration setting of the active substance in the different reservoir parts. Suitable active substances for the inventive plasters are all those which alone or with adjuvants are able to migrate into the skin. <br><br> The back layer covering the active substance reservoir on the skin remote side can be permeable or impermeable. It must be flexible and, as a result of the mechanical stabilization of the plaster, serves to remove part of the active substance reservoir. If components of the reservoir or the incorporated active substances are volatile, <br><br> then the back layer must be impermeable to these substances. It can be in one or multi-layer form. Suitable materials for the production thereof are e.g. polymeric substances, such as polyethylene, polypropylene, polyesters and polyamides. Further materials can be metal foils, such as e.g. aluminium foil, either alone or coated with a polymeric substrate. Permeable back layers are e.g. textile fabrics, such as non-woven fabrics and the like, but also porous polymer materials. The back layer can optionally carry a marking for indicating the optimum plaster removal direction. Optionally peel-off layers are provided between the active substance reservoir parts in place of a gap. They can be constituted by the same materials as described hereinbefore for the separating layer between the active substance reservoir parts and the back layer. The protective layer detachable prior to application and which covers the skin side contact adhesive surfaces can be made from the same material as used for making the back layer, provided that they can be made detachable, e.g. by applying a silicone layer. Other detachable protective layers, as known to the Expert in the field of plasters and in particular plasterlike therapeutic systems are e.g. polytetrafluoroethylene, treated paper, cellophane, polyvinylchloride, etc. To facilitate detach-ability, the protective layer can be provided with removal aids in per se known manner. The protective layer can also be larger than the plaster, e.g. if several plasters are arranged on an uninterrupted <br><br> it <br><br> -1 <br><br> &lt;ff;t <br><br> Vr' $:• <br><br> I <br><br> I <br><br> o <br><br> i f <br><br> \ <br><br> I <br><br> ! kj u <br><br> 22 3 8 9 4 <br><br> - 14 - <br><br> web of the protective layer material. <br><br> Contact adhesive layers used for the inventive plasters can be constituted by all physiologically unobjectionable contact adhesives which are inert to active substances and other active substance reservoir components, e.g. can be based on rubber, rubber-like, synthetic homo-co- or block polymers, polyacrylates and their copolymers,' poly-urethanes and silicones. <br><br> f The inventive plaster can be produced by all known plaster technology methods. This is demonstrated in the following production example for a plaster with a two-part active substance reservoir. <br><br> Production Example. <br><br> In a roller application process to a film or foil given a repelling finish by siliconizing and which serves as an intermediate covering, is applied an active substance-containing reservoir material solution and which, after drying at 65°C, forms a contact adhesive layer of <br><br> 2 <br><br> 55 g/m and having the following composition: <br><br> 1. Acrylate copolymer I 68.86 parts by weight <br><br> 2. Acrylate copolymer II 10.39 parts by weight <br><br> 3. P0E-(10)-oleyl alcohol 5.20 parts by weight <br><br> 4. Active substance 15.56 parts by weight <br><br> Acrylate copolymer I is Durotac 280-2516 of National Starch &amp; Chemical B.V., Netherlands; Acrylate copolymer II is Eudragit E100 of Rohm Pharma, Germany; P0E-(10)-oleyl alcohol is Brij 97 of Atlas Chemical Industries, GB. <br><br> Onto one half of the active substance-containing contact adhesive layer is applied a non-siliconized polyester film (thickness 0.036 mm) and to the other half the non-siliconized side of a one-sided, siliconized polyester film (thickness 0.036 mm). After removing the <br><br> 22 3 8 <br><br> 15 <br><br> intermediate covering ring-like active substance reservoir parts are punched out of the first half and are applied with the contact adhesive side to a siliconized, aluminium vapour-deposited polyester film (protective layer). From the second half are punched disk-like active substance reservoir parts with a slightly smaller diameter than the internal diameter of the rings into which they are centrally inserted with the contact adhesive side directed towards the protective layer. The open side of the thus obtained union is covered by a polyester-based, contact adhesively finished 0.015 mm thick back layer (Durotac 280-2516, 30 g/m dry), the outwardly directed side being adhesive-free. The distance between the active substance reservoir units is approximately 14 nun, so that the back layer is in contact with the protective layer between the units. The thus obtained laminate is then supplied to a production process, in which by circular punching at a distance of approximately 7 mm from the outer edge of the rings, all-round closed disk-like plasters are obtained, one or more of which are packed in sealed bags. <br><br> t <br><br> 223834 <br><br> WHAT//WE CLAIM IS:- <br><br> - 16 - <br><br></p> </div>

Claims (13)

1. Active substance-containing plaster for the controlled administration of active substances to the skin, which has a back and a skin side, with a back layer, an active substance reservoir divided substantially perpendicularly to the skin contact surface of the plaster and having one or more active substances, a contact adhesive device on the skin side and optionally a cover layer detachable prior to the application of the plaster, in which it Is possible to reduce the active substance release surface of the plaster by a predetermined amount through the removal
2. * • .;of part of the active substance reservoir, characterized in that at least one active substance reservoir part is detachable from the skin, whilst leaving behind one or more active substance reservoir parts >;the part of the active substance reservoir remaining on the skin having a better adhesion to the skin than to the back layer.;2.
3. Active substance-containing plaster according to claim 1, characterized in that the active substance reservoir Is In two parts.;3.
4. Active substance-containing plaster according to claim 1, characterized in that the active substance reservoir Is in three parts.;4 .
5. Active substance-containing plaster according to one Uj.
6. UiC preceding claims, characterized in that one active substance reservoir part completely surrounds one or more other active substance reservoir parts, considered in a flat or surface manner.;■f;223894;- 17 -;©;5.
7. Active substance-containing plaster according to claim. 4;characterized in that one active substance reservoir part annularly surrounds one or more other active substance reservoir parts •;Active substance-containing plaster according to one or more of the claims 1 to 4 , characterized in that the release surface-size ratio of one active substance reservoir part to another is between 1:1 and 1:10.;7.
8. Active substance-containing plaster according to one of the preceding claims, characterized in that the same active substance or same active substance combination is present In all the active substance reservoir parts.;8.
9. Active substance-containing plaster according to one of the claims 1 to nS characterized in that in at least one active substance reservoir part there is a different active substance/active substance combination as compared with the other active substance reservoir part.;9'.
10. Active substance-containing plaster according to one of the preceding claims, characterized in that the active substances have a topical or systemic action. ^;| 20 Process for the controlled administration to non-human animals of one or more active;1 (^j substances to the skin by means of a plaster according to one;! of the preceding claims, characterized by the adhesion to the;| skin of a plaster having optionally several active substances^;and/or the same active substance in different or identical concen-^;tratlons in different active substance reservoir parts which can be separated from one another and removal of one or more plaster parts with in each case one or more active substance reservoir parts after a predetermined time and whilst leaving>;behind a plaster residue with at least one active substance;»;I .;- 18 -;223834;reservoir part on the skin, as well as optionally repeating the last stage after a predetermined period of tine.;
11. Use of the active substance-containing plaster according to one of the preceding claims 1-9 for local and systemic, transdermal active substance administration in non-human medicine, or in cosmetics.;
12. An active substance-containing plaster as claimed in claim 1, substantially as herein described with reference to any one of the drawings.;•» * •
13. A process for the controlled administration of one or more active substances to the skin as claimed in claim 4^' substantially as herein described with reference to any one of the drawings. O o LTS LOHMANN THERAPIE-SYSTEME GMBH & CO/KG by their attorneys BALDWIN SON & CAREY
NZ223894A 1987-04-28 1988-03-15 Active substance-containing plaster for controlled administration of active agents to skin NZ223894A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873714140 DE3714140A1 (en) 1987-04-28 1987-04-28 ACTIVE SUBSTANCE PLASTER FOR THE CONTROLLED ADMINISTRATION OF ACTIVE SUBSTANCES TO THE SKIN, ITS USE AND METHOD FOR THE CONTROLLED ADMINISTRATION OF ACTIVE SUBSTANCES TO THE SKIN

Publications (1)

Publication Number Publication Date
NZ223894A true NZ223894A (en) 1990-11-27

Family

ID=6326433

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ223894A NZ223894A (en) 1987-04-28 1988-03-15 Active substance-containing plaster for controlled administration of active agents to skin

Country Status (28)

Country Link
EP (1) EP0288734B1 (en)
JP (1) JP2683264B2 (en)
KR (1) KR910002250B1 (en)
AT (1) ATE69962T1 (en)
AU (1) AU627422B2 (en)
CA (1) CA1316062C (en)
CZ (1) CZ278969B6 (en)
DD (1) DD281349A5 (en)
DE (2) DE3714140A1 (en)
DK (1) DK166193C (en)
ES (1) ES2027720T3 (en)
FI (1) FI91599C (en)
GR (1) GR3003289T3 (en)
HR (1) HRP920828B1 (en)
HU (1) HU204203B (en)
IE (1) IE61005B1 (en)
IL (1) IL85859A (en)
MY (1) MY103355A (en)
NO (1) NO172278C (en)
NZ (1) NZ223894A (en)
PH (1) PH25091A (en)
PL (1) PL161617B1 (en)
PT (1) PT87345B (en)
SI (1) SI8810781B (en)
SK (1) SK288388A3 (en)
WO (1) WO1988008318A1 (en)
YU (1) YU47056B (en)
ZA (1) ZA881739B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725669B2 (en) * 1988-12-23 1995-03-22 日東電工株式会社 Pharmaceutical formulation for transdermal administration
DE3844247A1 (en) * 1988-12-29 1990-07-12 Minnesota Mining & Mfg DEVICE, IN PARTICULAR PLASTER FOR TRANSDERMAL ADMINISTRATION OF A MEDICINAL PRODUCT
DE3901551A1 (en) * 1989-01-20 1990-07-26 Lohmann Therapie Syst Lts SUPERFICIAL THERAPEUTIC SYSTEM WITH AN ANTINEOPLASTIC ACTIVE SUBSTANCE, IN PARTICULAR 5-FLUORURACIL
DE4020144A1 (en) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Patches for topical or transdermal drug delivery - with adhesive layer contg. polyacrylate adhesive and film former
DE4110027C2 (en) * 1991-03-27 1996-08-29 Lohmann Therapie Syst Lts Process for packaging transdermal therapeutic patches
GB2273044B (en) * 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
FR2728463A1 (en) * 1994-12-21 1996-06-28 Lhd Lab Hygiene Dietetique TRANSDERMIC SYSTEM FOR SIMULTANEOUS DELIVERY OF SEVERAL ACTIVE PRINCIPLES
DE29514849U1 (en) * 1995-09-15 1995-11-16 Weyergans Rudolf Cellulite patch
FR2749514B1 (en) * 1996-06-11 1998-08-07 Hoechst Marion Roussel TRANSDERMAL SYSTEMS CONTAINING 2 ACTIVE INGREDIENTS IN SEPARATE COMPARTMENTS, THEIR PREPARATION METHOD AND THEIR APPLICATION AS A MEDICAMENT
DE19820999A1 (en) * 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Layered medicinal adhesive plaster with high holding power and flexibility
DE19911262C2 (en) * 1999-03-13 2003-04-10 Scs Skin Care Systems Gmbh Device for dispensing cosmetic active ingredients
DE19923427A1 (en) * 1999-05-21 2000-11-23 Lohmann Therapie Syst Lts Device for improved delivery of active agents to skin, useful e.g. for administering opiates, contains agent that increases local skin temperature or blood flow
DE10042412B4 (en) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transceiver for bus subscriber of bus system of building system engineering, has two wires, where microcontroller is connected with receiver unit over connection on one hand, which is connected to two wires of bus system
GB2383282B (en) 2002-04-02 2004-06-16 Crane Electronics Torque sensing tool
DE102004009903A1 (en) * 2004-02-26 2005-09-22 Grünenthal GmbH Patch with reduced skin irritation
EP2000119A1 (en) * 2007-06-08 2008-12-10 Royal College of Surgeons in Ireland Wound dressings
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
JP5386205B2 (en) * 2009-03-19 2014-01-15 リンテック株式会社 Transdermal patch
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
WO2017117554A1 (en) 2015-12-30 2017-07-06 Corium International, Inc. Systems and methods for long term transdermal administration
JP7174632B2 (en) 2016-06-23 2022-11-17 コリウム, インコーポレイテッド Adhesive matrix with hydrophilic and hydrophobic domains and therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297995A (en) * 1980-06-03 1981-11-03 Key Pharmaceuticals, Inc. Bandage containing attachment post
US4622031A (en) * 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device

Also Published As

Publication number Publication date
YU78188A (en) 1989-12-31
SI8810781A (en) 1996-12-31
CZ288388A3 (en) 1994-04-13
IE61005B1 (en) 1994-09-07
KR890700375A (en) 1989-04-24
PT87345B (en) 1995-03-01
EP0288734B1 (en) 1991-12-04
PH25091A (en) 1991-02-19
DE3866582D1 (en) 1992-01-16
DK166193B (en) 1993-03-22
AU627422B2 (en) 1992-08-27
DK722888D0 (en) 1988-12-23
MY103355A (en) 1993-06-30
KR910002250B1 (en) 1991-04-08
ATE69962T1 (en) 1991-12-15
PT87345A (en) 1989-05-12
YU47056B (en) 1994-12-28
FI91599B (en) 1994-04-15
SK278466B6 (en) 1997-06-04
FI886019A (en) 1988-12-28
NO884530L (en) 1988-11-03
AU1489488A (en) 1988-12-02
PL272134A1 (en) 1989-05-16
CA1316062C (en) 1993-04-13
GR3003289T3 (en) 1993-02-17
HUT53294A (en) 1990-10-28
WO1988008318A1 (en) 1988-11-03
HRP920828B1 (en) 1998-02-28
IL85859A (en) 1992-11-15
SK288388A3 (en) 1997-06-04
DD281349A5 (en) 1990-08-08
HRP920828A2 (en) 1994-04-30
IL85859A0 (en) 1988-09-30
CZ278969B6 (en) 1994-11-16
FI91599C (en) 1994-07-25
IE880834L (en) 1988-10-28
EP0288734A1 (en) 1988-11-02
NO172278B (en) 1993-03-22
ZA881739B (en) 1988-08-31
JPH01503383A (en) 1989-11-16
DK722888A (en) 1988-12-23
DK166193C (en) 1993-08-16
NO172278C (en) 1993-06-30
PL161617B1 (en) 1993-07-30
DE3714140C2 (en) 1989-03-09
HU204203B (en) 1991-12-30
DE3714140A1 (en) 1988-11-10
SI8810781B (en) 1999-04-30
ES2027720T3 (en) 1992-06-16
JP2683264B2 (en) 1997-11-26
NO884530D0 (en) 1988-10-11

Similar Documents

Publication Publication Date Title
US5538736A (en) Active substance-containing plaster for the controlled administration of active substances to the skin
NZ223894A (en) Active substance-containing plaster for controlled administration of active agents to skin
US5091186A (en) Biphasic transdermal drug delivery device
JP2527547B2 (en) Therapeutic device for drug administration
US4573996A (en) Device for the administration of an active agent to the skin or mucosa
CA2532981C (en) Ultra thin film transdermal/dermal or transmucosal/mucosal delivery system
IE910729A1 (en) Twin Patch Applicator
US4942037A (en) Transdermal delivery systems
JP4864204B2 (en) Transparent transdermal nicotine delivery device
AU709288B2 (en) Transdermal therapeutic system (tts) for the administration of drugs for treatment of drug dependency or drug addiction
AU2003226695B2 (en) Assembled unit consisting of individually separable transdermal therapeutic systems
CA1309661C (en) Transdermal delivery system
CZ284770B6 (en) Transdermal therapeutic system and the use thereof
JP2002517379A (en) A transdermal therapeutic system (TTS) for releasing an active substance to a living body through the skin and a method of applying the transdermal therapeutic system to the skin
US20050118245A1 (en) Assembled unit consisting of individually separable, transdermal, therapeutic systems
KR19980701419A (en) (s) -3-methyl-5- (1-methyl-2-pyrrolidenyl) -isoxazole or a transdermal therapeutic system for administering one of the pharmaceutically acceptable salts thereof
JPS62215521A (en) Skin and dermal and percutaneous patch having adhesive layerin discontinuous pattern
AU719171B2 (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts
MXPA97005324A (en) Transdermal therapeutic system for the supply of (s) -3-methyl-5- (1-methyl-2-pirrolidenyl) -isoxazole or any of its salts pharmaceutically ap
MXPA00001254A (en) Transdermal therapy system (tts) for releasing an active agent into an organism through the skin and method for applying said transdermal therapy system to the skin